Viking Therapeutics
VKTX
129 hedge funds and large institutions have $312M invested in Viking Therapeutics in 2022 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 34 increasing their positions, 34 reducing their positions, and 17 closing their positions.
333% more call options, than puts
Call options by funds: $22.8M | Put options by funds: $5.27M
330% more capital invested
Capital invested by funds: $72.4M → $312M (+$239M)
135% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 17
21% more funds holding
Funds holding: 107 → 129 (+22)
9.79% more ownership
Funds ownership: 34.71% → 44.5% (+9.8%)
0% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$6.7M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$5.78M |
| 3 |
Millennium Management
New York
|
+$5.71M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.94M |
| 5 |
D.E. Shaw & Co
New York
|
+$4.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$11.5M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$5.66M |
| 3 |
Walleye Capital
New York
|
-$3.95M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.32M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.16M |
VKTX Hedge Fund Activity: Q4 2022 in Review
129 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q4 2022, worth a combined $312M — up 330% from $72.4M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new VKTX positions and 17 closed out — a net gain of 23 holders — while 34 added to existing stakes and 34 trimmed.
The largest buyer was Boxer Capital, opening a new position worth an estimated $6.7M. The largest seller was Balyasny Asset Management, cutting an estimated $11.5M.
- 129 institutional investors held Viking Therapeutics (VKTX) as of Q4 2022, up from 107 in Q3 2022.
- Funds reported $312M of Viking Therapeutics stock for Q4 2022, up 330% quarter-over-quarter.
- 40 funds opened new Viking Therapeutics positions in Q4 2022 and 17 closed out, a net change of +23 holders.
- The largest Viking Therapeutics buyer in Q4 2022 was Boxer Capital, an estimated $6.7M added.
- The largest Viking Therapeutics seller in Q4 2022 was Balyasny Asset Management, an estimated $11.5M sold.
Based on aggregated 13F filings for Q4 2022.